Roivant Sciences (ROIV) News Today $12.00 -0.05 (-0.41%) (As of 09/18/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Organon to Buy Roivant's Dermatology Unit For Up to $1.2 BillionSeptember 18 at 7:02 PM | msn.comRoivant Sciences: Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1%September 18 at 7:02 PM | finanznachrichten.deRoivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2BSeptember 18 at 7:02 PM | finance.yahoo.comRoivant Flips a Skin Drug to OrganonSeptember 18 at 10:59 AM | barrons.comRoivant Sciences (NASDAQ:ROIV) Shares Gap Up to $12.05Roivant Sciences (NASDAQ:ROIV) Shares Gap Up to $12.05September 18 at 10:25 AM | marketbeat.comOrganon To Buy Dermavant For Around $1.2 BlnSeptember 18 at 8:59 AM | markets.businessinsider.comOrganon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 BillionSeptember 18 at 8:59 AM | marketwatch.comOrganon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%September 18 at 7:30 AM | globenewswire.comPekin Hardy Strauss Inc. Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Pekin Hardy Strauss Inc. acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 54,050 shares of the company's stock, valued at approximately $571,000. Several other hedge fSeptember 18 at 5:19 AM | marketbeat.comSofinnova Investments Inc. Has $19.75 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)Sofinnova Investments Inc. grew its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 86.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,868,412 shares of the company's stock after purchasing an additional 866,708 shares duSeptember 17 at 7:38 AM | marketbeat.comBayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal StudySeptember 16 at 3:25 PM | benzinga.comVivek Ramaswamy to Host New Roundtable Show for Fox NationSeptember 16 at 3:25 PM | msn.comBuy Rating Issued on Roivant Sciences Following Promising Pulmovant Data and Strategic Asset AcquisitionSeptember 16 at 3:25 PM | markets.businessinsider.comRhumbline Advisers Sells 70,856 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)Rhumbline Advisers decreased its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 7.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 886,493 shares of the company's stock after selling 70,856 shares dSeptember 13, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Given "Buy" Rating at HC WainwrightSeptember 13, 2024 | americanbankingnews.comL'action Roivant Sciences conserve sa recommandation d'achat, l'analyste voyant un potentiel dans le nouveau traitement de l'HP-PIDSeptember 12, 2024 | fr.investing.comRoivant Sciences (NASDAQ:ROIV) Given New $12.50 Price Target at Bank of AmericaSeptember 12, 2024 | americanbankingnews.comTD Cowen maintient sa recommandation d'achat sur les actions de Roivant Sciences, réitère sa note "Conserver"September 11, 2024 | fr.investing.comBuy Rating Affirmed on Roivant Sciences: Promising Drug Pipeline and Strategic AcquisitionsSeptember 11, 2024 | markets.businessinsider.comRoivant Sciences (NASDAQ:ROIV) PT Raised to $12.50 at Bank of AmericaBank of America raised their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a "neutral" rating in a research note on Wednesday.September 11, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday.September 11, 2024 | marketbeat.comPier Capital LLC Has $4.49 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Pier Capital LLC increased its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 29.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 425,087 shares of the company's stock after acquiring an additSeptember 11, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Rating Reiterated by Cantor FitzgeraldSeptember 11, 2024 | americanbankingnews.comTracking Baker Brothers Portfolio - Q2 2024 UpdateSeptember 11, 2024 | seekingalpha.comRoivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From BayerSeptember 11, 2024 | finance.yahoo.com40,000 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Monaco Asset Management SAMMonaco Asset Management SAM purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 40,000 shares of the company's stock, valued at approximately $423,000. Several otherSeptember 10, 2024 | marketbeat.comPulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society CongressSeptember 10, 2024 | globenewswire.comRoivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) ActivatorSeptember 10, 2024 | globenewswire.comTiff Advisory Services LLC Trims Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Tiff Advisory Services LLC reduced its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 10.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,032,752 shares of the company's stock afteSeptember 9, 2024 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Roivant Sciences in a research note on Monday.September 9, 2024 | marketbeat.comRoivant Provides Update on Graves' Disease Development ProgramSeptember 9, 2024 | globenewswire.comNew Mexico Educational Retirement Board Makes New $733,000 Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)New Mexico Educational Retirement Board purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 69,300 shares of the company's stock, valued at approximately $733,000. SeveralSeptember 8, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by EFG Asset Management Americas Corp.EFG Asset Management Americas Corp. boosted its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 78.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 138,690 shares of the company's stock afterSeptember 7, 2024 | marketbeat.comVivek Ramaswamy talks Fed policy, crypto, US economy agendasSeptember 5, 2024 | finance.yahoo.comAllspring Global Investments Holdings LLC Increases Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)Allspring Global Investments Holdings LLC lifted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 85.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 130,631 shares of the company's stock afteSeptember 4, 2024 | marketbeat.comStock Traders Purchase High Volume of Roivant Sciences Call Options (NASDAQ:ROIV)Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) saw unusually large options trading on Tuesday. Investors acquired 5,244 call options on the stock. This is an increase of approximately 124% compared to the average daily volume of 2,345 call options.September 3, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Privium Fund Management B.V.Privium Fund Management B.V. lowered its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 14.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 484,500 shares of the company's stocSeptember 1, 2024 | marketbeat.comInnovative Drugmaker Roivant Puts Up Really Healthy Sales NumbersAugust 31, 2024 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of "Moderate Buy" by AnalystsRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The aAugust 31, 2024 | marketbeat.comRoivant Sciences Trying To Close In On Key Technical BenchmarkAugust 30, 2024 | msn.comVivek Ramaswamy’s full-circle moment with tennis legend Andre Agassi: ‘Longest distance is between your mind & heart’August 26, 2024 | msn.comQ2 2025 Earnings Forecast for Roivant Sciences Ltd. Issued By HC Wainwright (NASDAQ:ROIV)Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) - Stock analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for shares of Roivant Sciences in a note issued to investors on Monday, August 19th. HC Wainwright analyst D. Tsao now forecasts that the company will earnAugust 22, 2024 | marketbeat.comRoivant Sciences: Inherently Risky Business Model, But Track Record ImpressesAugust 22, 2024 | seekingalpha.comSG Americas Securities LLC Invests $472,000 in Roivant Sciences Ltd. (NASDAQ:ROIV)SG Americas Securities LLC bought a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 44,637 shares of the company's stock, valuedAugust 21, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Roivant Sciences (NASDAQ:ROIV)HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Monday.August 19, 2024 | marketbeat.comIMVT Sep 2024 31.000 put (IMVT240920P00031000)August 18, 2024 | finance.yahoo.comIMVT Sep 2024 27.000 call (IMVT240920C00027000)August 18, 2024 | finance.yahoo.comIMVT Sep 2024 24.000 call (IMVT240920C00024000)August 17, 2024 | finance.yahoo.comIMVT Sep 2024 29.000 put (IMVT240920P00029000)August 17, 2024 | finance.yahoo.com"Future World No. 1" - Ben Shelton earns controversial Republican leader Vivek Ramaswamy's plaudits amid stellar Cincinnati Open 2024 runAugust 17, 2024 | msn.com Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. ROIV Media Mentions By Week ROIV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ROIV News Sentiment▼0.610.64▲Average Medical News Sentiment ROIV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ROIV Articles This Week▼175▲ROIV Articles Average Week Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRNA News Today BNTX News Today TEVA News Today BGNE News Today GMAB News Today SMMT News Today VTRS News Today RDY News Today PCVX News Today SRPT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ROIV) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
